The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Subscribe To Our Newsletter & Stay Updated
